Immunic (IMUX) Stock Price, News & Analysis

Company Overview

Immunic, Inc. is a clinical-stage biotechnology company developing orally administered therapies for chronic inflammatory and autoimmune diseases. The company focuses on selectively modulating the immune system while seeking to avoid broad immunosuppression, with an emphasis on conditions affecting the central nervous system and gastrointestinal tract.

Immunic’s lead investigational product is vidofludimus calcium, formerly known as IMU-838. The oral, selective dihydroorotate dehydrogenase inhibitor is being studied in clinical trials for multiple sclerosis, including relapsing and progressive forms of the disease. Immunic is also advancing earlier-stage programs such as IMU-856, which targets Sirtuin 6 and is being evaluated for intestinal disorders, and IMU-381, an investigational molecule intended for immune-mediated diseases.

Immunic was established in 2016 and became a publicly traded company in 2019 through a merger with Vital Therapies, subsequently adopting the Immunic name. The company maintains operations in the United States and Germany, including corporate activities in Waltham, Massachusetts, and research and development operations in Germany. Its programs are investigational and remain subject to clinical testing and regulatory review.

Key Stats

• Today's Range: $6.59 to $7.14
• 50-Day Range: $6.66 to $16.90
• 52-Week Range: $5.06 to $17.43
• Volume: 285,102 shs
• Average Volume: 481,138 shs
• Market Capitalization: $96.84 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $35.43
• Consensus Rating: Buy

Immunic Stock Analysis - MarketRank™

Immunic scored higher than 49% of companies evaluated by MarketBeat, and ranked 492nd out of 870 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Buy

Consensus Rating

Immunic has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 strong buy ratings, 7 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Immunic has a consensus price target of $35.43, representing about 399.0% upside from its current price of $7.10.

Amount of Analyst Coverage

Immunic has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Immunic are expected to grow in the coming year, from ($3.71) to ($2.74) per share.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

16.10% of the float of Immunic has been sold short.

Short Interest Ratio / Days to Cover

Immunic has a short interest ratio ("days to cover") of 4.56.

Change versus previous month

Short interest in Immunic has recently increased by 15.65%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Immunic does not currently pay a dividend.

Dividend Growth

Immunic does not have a long track record of dividend growth.

News and Social Media

• Score: 1.5 / 5
• News Sentiment: 0.38

News Sentiment

Immunic has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Immunic this week, compared to 4 articles on an average week.

Search Interest

Only 13 people have searched for IMUX on MarketBeat in the last 30 days. This is a decrease of -19% compared to the previous 30 days.

MarketBeat Follows

Only 7 people have added Immunic to their MarketBeat watchlist in the last 30 days. This is a decrease of -13% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Immunic insiders have not sold or bought any company stock.

Percentage Held by Insiders

5.49% of the stock of Immunic is held by insiders.

Percentage Held by Institutions

51.82% of the stock of Immunic is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/11/2026
• Today: 10/16/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:IMUX
• CIK: 1280776
• Web: www.imux.com
• Phone: (332) 255-9818
• Fax: 858-673-6843
• Employees: 95
• Year Founded: 2003

Price Target and Rating

• Average Price Target for Immunic: $35.43
• High Price Target: $70.00
• Low Price Target: $19.00
• Potential Upside/Downside: +399.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.38)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$97.17 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -157.89%
• Return on Assets: -107.88%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.05
• Quick Ratio: 5.05

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.55) per share
• Price / Book: -12.91

Miscellaneous

• Outstanding Shares: 13,640,000
• Free Float: 12,895,000
• Market Cap: $96.84 million
• Optionable: Optionable
• Beta: 1.45